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Three times daily administration of isosorbide dinitrate
may avoid much of the tolerance seen with more frequent
dosing. To determine the daylong pattern of the antianginal
effect of three times daily isosorbide dinitrate, eight men
with stable exertional angina and a positive exercise test
were studied. The subjects had demonstrated increased
exercise duration in response to oral isosorbide dinitrate
therapy and absence of complete tolerance to long-term
three times daily isosorbide dinitrate.
Treadmill exercise to onset of angina was performed
over 2 days at 8 AM, 9 AM, 11 AM, 1PM, 2 PM, 4 PM, 6 PM and
7 PM. On one day each patient received isosorbide dinitrate
at 8 AM, 1 PM and 6 PM in a previously titrated dose (mean
27.5 mg), which had been taken three times daily for at
least 2 weeks. On the other day at the same hours each
Isosorbide dinitrate has been first line therapy for angina
pectoris for decades. Despite initial controversy regarding
its ability to survive hepatic degradation and provide a
long-acting antianginal effect. numerous studies (1-3) have
shown that a single dose of oral isosorbide dinitrate can have
an exercise-prolonging effect lasting several hours. These
studies (1-3) in patients not taking isosorbide dinitrate on a
long-term basis have reported a duration of effect of an oral
dose of 4 to 8 h. Thadani et a!. (4), however, found that after
weeks of four times daily administration the duration of
effect of a single dose was reduced to 2 to 3 h. They
suggested that dosing every 2 to 3 h rather than every 6 h
would provide a more continuous therapeutic effect.
Recent emphasis in nitrate research has focused on the
problem of nitrate tolerance during long-term administra-
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patient received double blind a placebo identical in appear-
ance to isosorbide dinitrate.
One hour after the 8 AM dose of isosorbide dinitrate, mean
systolic blood pressure at rest had fallen by 19 mm Hg and
mean exercise time to angina increased by 200 s. However, by
11 AM exercise time had returned to control level. One hour
after the 1 PM dose of isosorbide dinitrate, exercise time
increased by a mean of 150 s but was again at control level 2
hlater. At 7PM, 1hafter the third dose of isosorbide dinitrate,
exercise duration increased by only 70 s.
Thus, at best, patients receiving long-term therapy with
isosorbide dinitrate three times daily obtain a total of no
more than 6 h of antianginal benefit during a 24 h period,
and the magnitude of the benefit declines with each suc-
ceeding dose during the day.
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tion. Studies (5-7) in patients receiving continuous intrave-
nous or transdermal nitroglycerin have demonstrated signif-
icant attenuation of response. if not complete tolerance.
within 24 h. Similarly, Parker et a!. (8) showed that four
times daily administration of isosorbide dinitrate, with the
last dose at 10 PM, results in almost complete tolerance
within I week. whereas three times daily administration,
with the last dose at 5 PM, can prevent tolerance to a
significant degree. Thus, the goal of a continuous and
constant therapeutic nitrate effect seems an elusive one. and
in usual clinical practice it is necessary to settle for consid-
erably less.
The purpose of the present study was to define over an
II h period in the course of I day the magnitude and duration
of the antianginal effect that can be obtained in optimal
circumstances from isosorbide dinitrate administrated three
times daily on a long-term basis.
Methods
Study patients. Eight men, aged 47 to 68 years. with
classic exertional angina pectoris were studied. Reproduc-
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ible provocation of typical anginal pain accompanied by at
least 1 mm of horizontal ST segment depression during
treadmill exercise was present in each patient. Five of the
patients had documented coronary artery disease by coro-
nary arteriography and four had had a previous myocardial
infarction, One patient had undergone coronary bypass
surgery and only one patient neither had undergone angiog-
raphy nor had a previous myocardial infarction, None of the
patients had hypertension or evidence of congestive heart
failure, and no patient had any condition contraindicating
beta-adrenergic blocking therapy, All patients were receiv-
ing a beta-adrenergic blocking agent. Seven of the eight
patients were receiving propranolol (mean daily dosage 160
mg, range 80 to 240) and one patient was receiving atenolol
(50 mg daily),
Training and exercise technique. The patients were
trained in treadmill exercise using a protocol conceptually
similar to the bicycle protocol of Redwood et aL (9). The
increment per 3 min stage was 1km/h (slightly less than the
Bruce protocol speed increment) with incline kept constant.
Starting incline and speed were individualized and were
chosen so that angina was provoked during the second 3 min
stage,
Heart rate and blood pressure at rest were measured after
the patient had been sitting for at least 5 min, Special care
was taken in measuring blood pressure at rest, and approx-
imately five determinations were made at 30 to 60 s intervals
to assure an accurate and stable determination, Exercise was
performed until the patient signaled the onset of definite
angina, at which point the exercise was stopped, The degree
of ST segment depression was used not as a formal end point
criterion but as an adjunct to ensure the accuracy and
constancy of the patient's subjective end point.
Training to the point of stahle performance (onset of
angina at a constant time ±30 s) typically required 10 to 15
exercise tests to angina over a 2 to 3 week period. During
this period the patient became thoroughly familiar with the
laboratory and staff, learned to signal the exact onset of
angina and overcame most of the training effect. Between
the beginning and the end of the training period there was
usually an improvement of at least one 3 min stage in
exercise capacity.
Isosorbide dinitrate titration. The method for evaluating
nitrate responsiveness and tolerance and performing dose
titration was the performance of two exercise tests, one
before and another 1 h after a dose of isosorbide dinitrate.
Criteria for an adequate response were at least a 2 min
increase in exercise duration to angina (typically, but not
invariably accompanied by a 15 to 20 mm Hg decrease in rest
systolic blood pressure) and the absence of a significant
improvement after the single-blind administration of a
matching placebo. Titration of dosage was begun with 10 mg
of isosorbide dinitrate or the patient's usual dose. Once an
adequate response to a given dose of isosorbide dinitrate was
obtained, the patient was instructed to take that dose three
times daily and was retested in 2 weeks. If there was no
longer at least a 2 min increase in exercise time after single
administration of the same dose, a larger dose was tested
and. if effective, was administered for 2 weeks three times
daily. In order to continue to the study trial, a patient had to
demonstrate continued responsiveness after 2 weeks of
isosorbide dinitrate administration. We generally stopped
titration if there was primary or secondary failure to respond
after the single dose had been increased to 40 mg, although
one patient's treadmill performance eventually stabilized
with a 60 mg dose.
Definitive trial. The definitive trial was designed to eval-
uate the antianginal effectiveness of three doses of isosor-
bide dinitrate given in the course of 1day every 5 h over an
11 h period in patients who had been taking the same doses
three times daily continuously for at least 2 weeks.
Patients reported to the exercise laboratory at 7:45 AM in
the fasting state except for their usual morning dose of
beta-adrenergic blocking agent that had been taken 1to 1.5 h
earlier. There was no standard time for taking the final daily
dose of isosorbide dinitrate, and on the previous day it had
been taken by the eight individual patients at the following
times: 3 PM, 5:30 PM, 6 PM, 6:30 PM, 7 PM (two patients), 9: 15
PM and 10:30 PM. A control exercise test was performed
according to the previously individualized treadmill protocol
after which the patient received a large, opaque capsule
containing either placebo or commercially available isosor-
bide dinitrate. On one of the study days the capsules
contained isosorbide dinitrate in the dose that had previously
been determined effective for the individual patient. On the
other day placebo capsules identical in appearance were
administered. Administration of the treatments was double
blind and randomized.
Drug administration was at 8 AM, and exercise testing to
angina was carried out at 9 AM, II AM and I PM. After the 1
PM test a second capsule identical to the one given at 8 AM
was administered and exercise testing was performed at 2
PM, 4 PM and 6 PM. After the 6 PM test a third capsule was
administered. and at 7 PM the final exercise test of the day
was carried out. The patient took the second daily dose of
propranolol and went home. After the 9 AM exercise test,
patients had a snack and after the 2 PM test, patients ate
lunch. The interval between trial days was at least 1day and
no more than 12 days. During the interval the patient
resumed the usual dose of isosorbide dinitrate three times
daily.
Statistical methods. Differences between group mean ex-
ercise test variables for tests conducted at the same hour on
the different study days or between different hours on the
same day were compared by means of Student's t tests after
the performance of an analysis of variance. An adjusted
p value was used to indicate statistical significance at the
938 BASSAN
ANTIANGINAL EFFECT OF ISOSORBIDE D1NITRATE












Figure 1. Mean duration of exercise to angina at different hours
during days on which placebo or isosorbide dinitrate (ISDN) was
administered. Capsules containing placebo or isosorbide dinitrate
were given to patients at 8 AM, I PM and 6 PM. See Table I for
p values.
0.05 level when multiple comparisons were made. Data arc
given as mean values ± SEM.
Ethics. The research nature of the study was explained to
each patient and informed consent was obtained. The study
was approved by the institutional committee on human
experimentation.
Results
Dosage of isosorbide dinitrate. The titrated doses of isos-
orbide dinitrate that the patients were taking three times
daily over the long term and that we tested singly ranged
from 10 to 60 mg (mean 27.5 mg). Although we generally
stopped titration at the 40 mg dose, in one patient we
continued to 60 mg, the dose at which his performance
eventually stabilized.
Time to angina (Fig. 1, Table 1). Mean exercise duration
Table 1. Mean Values (in seconds) for Exercise Duration on Days
During Which Either Placebo or Isosorbide Dinitrate
Was Administered
Isosorbide
Time Placebo Dinitrate p Value
8 AM 259 ± 18 280 ± 19 0.19
9 AM 278 ± 19 479 ± 68 0.002*
II AM 234 ± 10 307 ± 23 0.02
I PM 260 ± 13 283 ± 17 0.22
2 PM 262 ± 15 433 ± 69 0.004*
4 PM 233 ± 14 263 ± 12 0.03
6 PM 219 ± 10 239 ± 10 0.04
7 PM 232 ± 12 310 ± 18 0.001*
*Statistical significance at 0.05 level if p < 0.007.
to angina on the day placebo capsules were administered
varied little throughout the day. In contrast, I h after
administration of the 8 AM dose of isosorbide dinitrate
exercise duration rose 200 s from a mean of 280 ± 18 s to
479 ± 68 s (p < 0.001). By 3 h after the dose, exercise
duration had decreased almost to control level and was not
significantly different from the value after placebo. After the
second dose of isosorbide dinitrate at I PM, there was
another marked increase in exercise duration of 150 s, which
also dissipated within 3 h. The third dose of isosorbide
dinitrate at 6 PM produced a much smaller increase in
exercise time of only 70 s, although there was still a
statistically significant difference in comparison with the
effect of placebo.
Improvement in exercise duration after isosorbide dini-
trate administration was invariably accompanied by a delay
in the onset of ST depression and by a smaller amount of ST
depression than at the time when angina had occurred after
placebo administration. The amount of ST depression when
angina did occur after isosorbide dinitrate was approxi-
mately the same as after placebo.
Blood pressure (Fig. 2, Table 2). Rest systolic blood
pressure, measured just before the exercise test, decreased
from 121 ± 4 to 102 ± 6 mm Hg (p < 0.001) by I h after the
8 AM dose of isosorbide dinitrate. At 3h after the dose, blood
pressure was still markedly lowered, whereas by 5 h it had
risen to a level no different from that after placebo. A similar
pattern was observed after the second dose of isosorbide
dinitrate at I PM. The third dose of isosorbide dinitrate at 7
PM, however, produced almost no change in blood pressure,
although it was somewhat lower than the comparable pla-
cebo value, which had risen acutely. It should be noted that
blood pressure was still lowered at 3 h after an isosorbide
dinitrate dose even though exercise duration had returned
almost to control value.
Discussion
Magnitude-duration pattern of the antianginal effect of
isosorbide dinitrate. We have shown that in patients receiv-
ing long-term isosorbide dinitrate the immediate antianginal
effect of a dose can be quite marked. Unfortunately, how-
ever, the duration of the effect is relatively brief. We found
the effect present at I h after the dose was administered and
essentially gone 3 h after administration. It may be assumed
that the onset of effect was earlier than I h, yet the loss of
effect was quite likely before 3 h. The actual duration of
effect was probably not much greater than 2 h and the
ma[?nitudc of effect decreased with each succeedinR dose
during the day.
Thus, conventional three times daily administration of
isosorbide dinitrate results in a significantly increased angi-
nal threshold during probably no more than 6 h of a 24 h
period. Considering our current understanding of the impor-
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Table 2. Mean Values (in mm Hg) for Rest Systolic Blood
Pressure on Days During Which Either Placebo or Isosorbide
Cl Dinitrate Was Administered
%:
E PLACEBO Isosorbide§.
! Time Placebo Oinitrate p Value
:>
II
II 8 AM 121 :!: 5 121 :!: 4 0.8!
Q. 9 AM 119:!: 6 102 :!: 6 0.002*...
0
II AM 118 :!: 5 102 :!: 5 0.001*0j5
,g I PM 118:!: 5 114 :!: 8 0.36
0 2 PM 121 :!: 6 104 :!: 6 0.002*•>-
'" 90 4 PM 118 :!: 5 106 :!: 5 0.006*•.. 6 PM 120:!: 5 117 :!: 5 0.16a:
l8em 9 1 7 7 PM 128 :!: 5 116 :!: 6 0.01IIdn
Time of day
Figure 2. Mean systolic blood pressure at rest before exercise at
different hours during days on which placebo or isosorbide dinitrate
(ISDN) was administered. Capsules containing placebo or isosor-
bide dinitrate were given to patients at 8 AM. I PM and 6 PM. See
Table 2 for p values.
tance of a daily nitrate·free interval in preventing nitrate
tolerance (8), as well as the diminishing effect we observed
with successive doses during the day, it is highly unlikely
that more total doses or more frequent doses during a 24 h
period will be capable of increasing the overall antianginal
effect.
Comparison with previous studies. Thadani et al. (4)
found that the antianginal effect ofa single dose of isosorbide
dinitrate during long-term four times daily administration
was dissipated by 4 h after dose administration. Parker et al.
(8), studying patients receiving long-term three times daily
isosorbide dinitrate, found a marked diminution of the peak
effect at 3and 5 h after a single dose. Our investigation is the
only one to study the antianginal profile of repeated doses
throughout the day. We not only observed the same brief
duration of effect that Thadani et al. (4) and Parker et al. (8)
reported, but also found that the peak effect is attenuated
after the second daily dose and markedly diminished after
the third dose.
Influence of beta-adrenergic blocking therapy. It may be
asked whether the magnitude-duration pattern we observed
for the antianginal effect of isosorbide dinitrate was influ-
enced by the concomitant administration of propranolol
because both drugs undergo extensive first pass metabolism
in the liver. In a previous study (3) involving single dose
administration of isosorbide dinitrate to patients also receiv-
ing propranolol, we found a dose-response and magnitude-
duration pattern similar to that described by other investi-
gators who studied patients not receiving concomitant beta-
adrenergic blocking therapy. Furthermore, our current
results regarding the magnitude and duration of effect of a
single dose of isosorbide dinitrate are consistent with those
of previous investigators (4,8) who studied patients during
*Statistical significance at 0.05 level if p < 0.007.
sustained therapy with isosorbide dinitrate but without beta-
adrenergic blocking therapy.
Appropriateness of patient sample. Because our patients
were a small and selected group, it may be questioned
whether our conclusions are applicable to patients with
angina pectoris in general. in whom isosorbide dinitrate is
often used. The nature of our patients' coronary artery
disease and the clinical characteristics of their angina
seemed in no way unusual. They were probably more
responsive to nitrates and less tolerant than an unselected
study group would have been. Nonetheless, at the least, they
can be seen to constitute a valid pharmacotherapeutic model
for the very best that can be obtained with three times daily
isosorbide dinitrate treatment. There is no reason to assume
that isosorbide dinitrate administered three times daily over
the long term would have any longer duration of action in an
unselected group of patients with angina than in our group.
In fact, the antianginal effects of isosorbide dinitrate that
we observed were in all likelihood considerably greater than
those obtained in usual clinical practice. Our selection
procedure limited our subjects to patients who responded
well to nitrates and who maintained good responsiveness in
the face of continuous three times daily therapy. Further-
more. we carefully optimized isosorbide dinitrate dosage by
means of a painstaking titration process based on exercise
testing before and after a dose. It is unlikely that the average
patient treated in the usual empiric fashion would exhibit the
magnitude of antianginal effect that our patients did.
Conclusion. It appears that customary treatment with
isosorbide dinitrate three times daily is capable of providing.
at best. no more than very modest antianginal benefit.
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